Research map: Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease

Back to the article

Papers in this map

  1. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review · Zobair M. Younossi · 2023 · 3310 citations · Cited by this paper
  2. MetALD Molecular Signatures: What We Know, What We Lack, and How to Move Forward Through Integrated Multi-Omics · Miriam Longo · 2026 · Cites this paper
  3. APASL clinical practice guidelines on the management of chronic hepatitis B infection: a 2026 update · 2026 · Related
  4. A multisociety Delphi consensus statement on new fatty liver disease nomenclature · Mary Eugenia Rinella · 2023 · 3201 citations · Cited by this paper
  5. APASL STC on Wilson Disease; New Delhi 2026 · 2026 · Related
  6. Baveno VII – Renewing consensus in portal hypertension · Roberto de Franchis · 2021 · 2898 citations · Cited by this paper
  7. Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial · 2026 · Related
  8. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis · Stephen A. Harrison · 2024 · 1982 citations · Cited by this paper
  9. Phosphatidylethanol versus clinical criteria to diagnose alcohol use relapse after liver transplantation: a prospective cohort study · 2026 · Related
  10. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies · Siddharth Singh · 2014 · 1768 citations · Cited by this paper
  11. Precision medicine for G-CSF in ACLF: the biomarker gap · 2026 · Related
  12. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease · Laurent Castéra · 2019 · 1518 citations · Cited by this paper
  13. Response to letter to editor—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon · 2026 · Related
  14. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease · Arun Jayant Sanyal · 2021 · 1134 citations · Cited by this paper
  15. Methodological Considerations in the MAFLD-MASLD Dichotomy for Cardiac Risk Assessment · 2026 · Related
  16. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis · Arun J. Sanyal · 2025 · 985 citations · Cited by this paper
  17. Obstructive sleep apnea mediates the association between body mass index and metabolic dysfunction-associated steatotic liver disease in patients with obesity · 2026 · Related
  18. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise · Vincent Wai‐Sun Wong · 2018 · 632 citations · Cited by this paper
  19. Gout is independently associated with occult hepatic fibro-inflammation independent of obesity: a multi-cohort study using MRI-cT1 and elastography · 2026 · Related
  20. Noninvasive, Quantitative Assessment of Liver Fat by MRI‐PDFF as an Endpoint in NASH Trials · Cyrielle Caussy · 2018 · 577 citations · Cited by this paper
  21. FXR overexpression promotes liver regeneration through inducing FGF2 activation in APAP-induced acute liver injury · 2026 · Related
  22. The Timeline Followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties. · William S. Fals-Stewart · 2000 · 543 citations · Cited by this paper
  23. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis · Ferenc Emil Mózes · 2021 · 520 citations · Cited by this paper
  24. Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research · Daniel Almirall · 2014 · 464 citations · Cited by this paper
  25. Steatotic liver disease · Mads Egerod Israelsen · 2024 · 350 citations · Cited by this paper
  26. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study · Luca Saverio Belli · 2016 · 345 citations · Cited by this paper
  27. Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis · Jonathan G. Stine · 2020 · 282 citations · Cited by this paper
  28. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis · Michael S. Middleton · 2017 · 279 citations · Cited by this paper
  29. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease · Maja Sofie Thiele · 2018 · 273 citations · Cited by this paper
  30. Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease · Huapeng Lin · 2024 · 242 citations · Cited by this paper
  31. Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: Noninvasive Assessment with MR Elastography · Donghee Kim · 2013 · 230 citations · Cited by this paper
  32. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study · Yasaman Vali · 2023 · 217 citations · Cited by this paper
  33. The win ratio approach for composite endpoints: practical guidance based on previous experience · Björn Redfors · 2020 · 209 citations · Cited by this paper
  34. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease · David Martí Aguado · 2024 · 202 citations · Cited by this paper
  35. Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee · S. Percy Ivy · 2010 · 201 citations · Cited by this paper
  36. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events · Jerome Boursier · 2022 · 200 citations · Cited by this paper
  37. Non-invasive diagnosis and biomarkers in alcohol-related liver disease · Christophe Moreno · 2019 · 183 citations · Cited by this paper
  38. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study · Mads Egerod Israelsen · 2024 · 171 citations · Cited by this paper
  39. Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease · Juan Pablo Arab · 2024 · 170 citations · Cited by this paper

Source: OpenAlex (CC0)